.mp. OR (meat* adj1 product*).mp. OR (animal* adj1 protein*).mp. OR (animal* adj1 product*).mp. OR (fish* adj1 protein*).mp. OR (fish* adj1 product*).mp. OR (poultry adj1 protein*).mp. OR (poultry adj1 product*).mp. OR (chicken* adj1 protein*).mp. OR (chicken* adj1 product*).mp. OR (egg* adj1 protein*).mp. OR (egg* adj1 product*).mp. OR (milk adj1 protein*).mp. OR (milk adj1 product*).mp. OR (dairy adj1 protein*).mp. OR (dairy adj1 product*).mp.)
(exp omnivore/ OR omnivor*.mp. OR (conventional adj3 diet*).mp. OR (normal adj3 diet*).mp. OR (regular adj3 diet*).mp. OR (mixed adj3 diet*).mp. OR exp Meat/ OR exp egg/ OR exp dairy product/ OR (meat* adj1 protein*).mp. OR (meat* adj1 product*).mp. OR (animal* adj1 protein*).mp. OR (animal* adj1 product*).mp. OR (fish* adj1 protein*).mp. OR (fish* adj1 product*).mp. OR (poultry adj1 protein*).mp. OR (poultry adj1 product*).mp. OR (chicken* adj1 protein*).mp. OR (chicken* adj1 product*).mp. OR (egg* adj1 protein*).mp. OR (egg* adj1 product*).mp. OR (milk adj1 protein*).mp. OR (milk adj1 product*).mp. OR (dairy adj1 protein*).mp. OR (dairy adj1 product*).mp.) (omnivor*.mp. OR (conventional adj3 diet*).mp. OR (normal adj3 diet*).mp. OR (regular adj3 diet*).mp. OR (mixed adj3 diet*).mp. OR exp egg proteins, dietary/ OR exp milk proteins/ OR exp meat/ OR exp eggS/ OR exp dairy products/ OR exp milk/ OR (meat* adj1 protein*).mp. OR (meat* adj1 product*).mp. OR (animal* adj1 protein*).mp. OR (animal* adj1 product*).mp. OR (fish* adj1 protein*).mp. OR (fish* adj1 product*).mp. OR (poultry adj1 protein*).mp. OR (poultry adj1 product*).mp. OR (chicken* adj1 protein*).mp. OR (chicken* adj1 product*).mp. OR (egg* adj1 protein*).mp. OR (egg* adj1 product*).mp. OR (milk adj1 protein*).mp. OR (milk adj1 product*).mp. OR (dairy adj1 protein*).mp. OR (dairy adj1 product*).mp.) AND (exp lipoproteins/ OR exp cholesterol/ OR exp hyperlipidemias/ OR (lipid or lipids).mp. OR (cholesterol or cholesterols).mp. OR hdl.mp. OR ("high density lipoprotein" or "high density lipoproteins").mp. OR ldl.mp. OR ("low density lipoprotein" or "low density lipoproteins").mp. OR apolipoprotein*.mp. OR (hyperlipemia* or hyperlipaemia*).mp. OR (hyperlipidemia* or hyperlipidaemia*).mp. OR (lipidemia* or lipidaemia*).mp. OR (lipemia* or lipaemia*).mp. OR (lipemic or lipaemic).mp.) (exp lipoproteins/ OR exp cholesterol/ OR exp hyperlipidemias/ OR (lipid or lipids).mp. OR (cholesterol or cholesterols).mp. OR hdl.mp. OR ("high density lipoprotein" or "high density lipoproteins").mp. OR ldl.mp. OR ("low density lipoprotein" or "low density lipoproteins").mp. OR apolipoprotein*.mp. OR (hyperlipemia* or hyperlipaemia*).mp. OR (hyperlipidemia* or hyperlipidaemia*).mp. OR (lipidemia* or lipidaemia*).mp. OR (lipemia* or lipaemia*).mp. OR (lipemic or lipaemic).mp.) (exp lipoproteins/ OR exp cholesterol/ OR exp hyperlipidemias/ OR (lipid or lipids).mp. OR (cholesterol or cholesterols).mp. OR hdl.mp. OR ("high density lipoprotein" or "high density lipoproteins").mp. OR ldl.mp. OR ("low density lipoprotein" or "low density lipoproteins").mp. OR apolipoprotein*.mp. OR (hyperlipemia* or hyperlipaemia*).mp. OR (hyperlipidemia* or hyperlipidaemia*).mp. OR (lipidemia* or lipidaemia*).mp. OR (lipemia* or lipaemia*).mp. OR (lipemic or lipaemic).mp.) 2 limit 1 to animals limit 1 to animals 1 not (exp infant formula/ OR exp milk, human/) 3 limit 2 to human limit 2 to human 4 2 not 3 2 not 3 5 1 not 4 1 not 4 6 5 not (exp infant formula/ OR exp milk, human/) 5 not (exp breast milk/ or exp infant formula/)
For all databases, the original search date was December 6, 2016; updated search was performed on September 10, 2017. (6) 42 N (42M) 45 (15) 32 N,PM (19) 20 N (4M,16W) (27) 12 N (12M) 31. (28) (32) (N) (8) , and median age and range were used for Puksa et al. 2004 (73) . † Baseline BMI values (kg/m2). Baseline body weight (kg) values are only reported when no data on body weight were available. Waist circumference (cm) was used for the study by van Nielen et al. 2014 (92) as neither were available. ‡ Animal protein source. Multiple animal protein intervention arms within the same trial are separated by a comma. § Food form indicates whether test foods were in the form of whole foods (whole) and/or isolated protein supplements (protein). || Amount of protein substitution, per day unless otherwise indicated. Where data for grams of substitution was unavailable, grams/2000kcal, percentage protein replacement, grams per kilogram body weight, or serving sizes were used as available. Studies describing replacement of "most" protein are displayed as >75%. Multiple dosage levels within the same trial are separated by a comma. ¶ Background diet as described by study protocol. Where specific diets were not indicated, dietary breakdowns are listed as energy from (carbohydrate:fat:protein) where given, and where no information was given habitual diets were assumed. NCEP Step 1 diet has <30% fat, <1/3 saturated fat, and <300mg cholesterol. NCEP Step 2 diet has <30% fat, <1/4 saturated fat, and <200mg cholesterol. Nephropathy diet contains 0.8g protein/kg body weight. Hemodialysis diet contains 35%F, 1.2g protein/kg body weight, and 32-35kcal/kg body weight. Plant-based diet includes vegetarian, lacto-vegetarian, and lacto-ovo-vegetarian. # Agency funding consists of funding from government, university, or not-for-profit health agency sources. The following studies had declared conflicts of interest: Gardner et al 2007 (30) , Haub et al 2005 (34) , Hermansen et al 2001 (35) , Jenkins et al 2010 (44) , Maki et al 2010 (59) , Mercer et al 1987 (63) , Padhi et al 2015 (69) , Tonstad et al 2002 (90) , and West et al 2005 (98) . None of the other studies declared any conflicts of interest. ** Includes baseline data before drop-outs where final data were not available for study characteristics † † For Hill et al. 2015 (36) , the background diet followed the DASH diet except for one arm of the animal protein arm which had increased protein content ‡ ‡ The data from Markova et al. 2015 (60) are not yet published; BMI data from this study describe the first 30 patients enrolled § § Kestin et al. 1989 (45) used an incomplete crossover design with three arms Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10. Paired analyses were applied to all crossover trials. The studies by Duane et al. 1999 (26) , Lovati et al. 1987 (56) , Sirtori et al. 2002 (80) , and Van Horn et al. 2001 (91) were missing variance data, which were imputed using the average standard of the mean differences across included trials based on the respective trial's sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance random-effects models. Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I 2 , levels of ≥50% represented substantial heterogeneity. (26) , Lovati et al. 1987 (56) , Sirtori et al. 2002 (80) , and Van Horn et al. 2001 (91) were missing variance data, which were imputed using the average standard of the mean differences across included trials based on the respective trial's sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance fixed-effects models. Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I 2 , levels of ≥50% represented substantial heterogeneity. Figure S5 . Post-Hoc Subgroups. Point estimates for each subgroup level (squares) are the pooled effect estimates. The dashed line represents the pooled effect estimate for the overall (total) analysis. The residual I 2 value indicates the interstudy heterogeneity unexplained by the subgroup. Statistically significant pairwise subgroup effect modification by meta-regression analyses at P < 0.05. LF=low-fat; N=normal; NIF=no isoflavones; Pre-MS=pre-metabolic syndrome. The pooled effect estimate (diamond) is shown. Paired analyses were applied to all crossover trials. The study by Duane et al. 1999 (26) was missing variance data, which was imputed using the average standard of the mean differences across included trials based on the respective trial's sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance random-effects models.
100.0%
Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I 2 , levels of ≥50% represented substantial heterogeneity. (26) was missing variance data, which was imputed using the average standard of the mean differences across included trials based on the respective trial's sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance fixed-effects models. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I 2 , levels of ≥50% represented substantial heterogeneity. Figure S10 . Apo-B Forest Plot, fixed-effects model. HC=hypercholesterolemic; IF=isoflavones; LF=low-fat; N=normal; NIF=no isoflavones. The pooled effect estimate (diamond) is shown. Paired analyses were applied to all crossover trials. Data are expressed as MDs with 95% CIs, using generic inverse-variance fixed-effects models. Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I 2 , levels of ≥50% represented substantial heterogeneity. 
